Pharmacy Times is the leading US pharmacist-facing trade publication and one of the most cited sources for professional-practice guidance on the 2026 peptide story. The outlet's coverage runs across three threads. The first is the RFK Jr. peptide reclassification: a June 9 analyst piece broke down what HHS Secretary Robert F. Kennedy Jr.'s February 27 announcement (14 of 19 Category 2 peptides moving back to Category 1) actually means for licensed compounding pharmacies, including the procedural requirement that PCAC review on July 23-24 must precede 503A bulks list addition.
The second is GLP-1 compounding regulation. A May 2026 piece (Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices) covered the November 2025 TrumpRx pricing pact and the $245 Medicare/Medicaid GLP-1 list price. A late-May piece (FDA Moves to Permanently Close the Door on Compounded GLP-1s) walked the proposed 503B exclusion (semaglutide, tirzepatide, liraglutide) with comment window through June 29. A June 27 interview with Annie Lambert, PharmD (Wolters Kluwer clinical program manager for compliance solutions), provided operational guidance on how 503A pharmacies should adjust to the post-503B-narrowing landscape, including patient counseling on pharmacy licensure verification and the distinction between compounded and FDA-approved products.
The third is broader patient-safety framing. The outlet published 'Peptides Are Everywhere — So It's Time for a Serious Conversation' (May 8) arguing that the FDA's regulatory gap is itself a patient-safety risk given existing utilization. Stories tagged here track Pharmacy Times peptide-specific coverage and the pharmacist-facing professional guidance ecosystem.
Pharmacy Times published an interview with Annie Lambert, PharmD, BCSCP, Wolters Kluwer's clinical program manager for compliance solutions, on Friday June 27, 2026, walking pharmacists through the operational response to the FDA's proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Three working points framed the guidance: the FDA's move signals a narrowing of large-scale compounding rather than an outright ban (503A pharmacies can still compound these agents under increased scrutiny); pharmacists should demonstrate fluency in the new regulatory rules and help patients weigh manufacturer-assistance programs (NovoCare $149-499/month, LillyDirect $299-449/month self-pay), direct-to-consumer channels, and the Medicare GLP-1 Bridge launching Wednesday July 1; patients should verify pharmacy licensure, question medication sourcing, and understand the distinction between FDA-approved branded products and compounded preparations. The guidance is the highest-profile professional-practice resource published in the comment-deadline week and is likely to circulate widely among the National Community Pharmacists Association and Alliance for Pharmacy Compounding memberships.
Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.
Pharmacy Times ran a Ferry Ossendorp Q&A on May 5 walking through the mechanistic case for peptide-based cancer vaccines: T cells recognize small peptides presented on the surface of tumor cells, and synthetic peptides matched to tumor antigens can be used to vaccinate the immune system to recognize and target those tumors. Ossendorp's own work showed that knowledge of a tumor's antigen profile combined with peptide vaccination can protect against very aggressive tumors in animal models. The piece sits inside a 2026 peptide-vaccine pipeline with 31 active personalized cancer-vaccine trials registered (more than dendritic-cell or RNA-vaccine platforms), the BioVaxys MVP-S survivin program heading to ASCO 2026, the Greenwich GP2/GLSI-100 FLAMINGO-01 readout, and the BriaCell Bria-IMT Phase 3.